Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Extreme thiopurine metabolite accumulation and life-threatening myelotoxicity due to cumulative pharmacogenetic susceptibility in Crohn’s disease. Local targets link to admitted publications; unresolved targets remain external evidence.
Infliximab, azathioprine, or combination therapy for Crohn’s disease
10.1056/nejmoa0904492 · 2010 · External reference
Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations
10.1016/j.cgh.2009.07.019 · 2009 · External reference
Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes
10.1002/cpt.1304 · 2019 · External reference
HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
10.1002/pbc.21039 · 2007 · External reference
Risk factors for thiopurine-induced leukopenia in IBD: a systematic review and meta-analysis
10.1111/apt.15403 · 2019 · External reference
Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease
10.1001/jama.2019.0709 · 2019 · External reference
Unresolved reference
External reference
Association of ITPA gene polymorphisms with adverse effects of azathioprine and 6-mercaptopurine therapy: a systematic review and meta-analysis
10.1038/s41397-021-00255-3 · 2022 · External reference
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients
10.1038/s41397-024-00341-2 · 2024 · External reference
